

별첨 2

배제문헌

문헌배제사유

1. 동물연구 또는 전임상시험
2. 원저가 아닌 연구(중설, letter, comment 등)
3. 한국어나 영어로 출판되지 않은 문헌
4. 동료심사된 학술지에 게재되지 않은 문헌
5. 파킨슨병 의심환자 및 파킨슨병을 대상으로 수행하지 않은 문헌
6. F-18 FP-CIT PET, PET/CT를 수행하지 않은 문헌
7. 적절한 의료결과를 하나 이상 보고하지 않은 문헌
8. 증례보고(3인 이하)

연번	서지정보	배제 사유
국내문헌		
1	An HJ, Seo S, Kang H, Choi H, Cheon GJ, Kim H-J, et al. MRI-Based Attenuation Correction for PET/MRI Using Multiphase Level-Set Method. The Journal of nuclear medicine. 2016;57(4):587-93.	7
2	Choi H, Cheon GJ, Kim H-J, Choi SH, Lee JS, Kim Y-i, et al. Segmentation-Based MR Attenuation Correction Including Bones Also Affects Quantitation in Brain Studies: An Initial Result of 18F-FP-CIT PET/MR for Patients with Parkinsonism. The Journal of nuclear medicine. 2014;55(10):1617-22.	7
3	Hwang D, Kim KY, Kang SK, Seo S, Paeng JC, Lee DS, et al. Improving the Accuracy of Simultaneously Reconstructed Activity and Attenuation Maps Using Deep Learning. The Journal of nuclear medicine. 2018;59(10):1624-9.	7
4	Hwang I, Ha SW, Yang Y, Kim SM. Hydrocephalus in Patient with Multiple System Atrophy: Innocent Bystander or Guilty Party? Dement Neurocogn Disord. 2016;15(2):49-51.	8
5	Im H-J, Hwang DW, Lee HK, Jang J, Lee S, Youn H, et al. In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease. Molecular imaging. 2013;12(4):224-34.	1
6	Jin S, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clinical nuclear medicine. 2017;42(2):80-7.	7
7	Jincheol S, Youngjeon L, Hyeon-Gu Y, Chang-Yeop J, Kang-Jin J, Seung-Ho P, et al. Novel strategy of MPTP administration for stable parkinsonian symptoms in non-human primates. 한국실험동물학회 학술발표대회 논문집. 2017;2017(2):110-.	1

연번	서지정보	배제 사유
8	Kim BS, Jang SJ, Eo JS, Park EK, Kim YK, Kim JM, et al. The Discriminating Nature of Dopamine Transporter Image in Parkinsonism: The Competency of Dopaminergic Transporter Imaging in Differential Diagnosis of Parkinsonism: 123I-FP-CIT SPECT Study. Nucl Med Mol Imaging. 2007;41(4):272-9.	6
9	Kim J, Kim J-M, Kim YK, Shin JW, Choi SH, Kim SE, et al. Dopamine Transporter SPECT of a Liver Cirrhotic with Atypical Parkinsonism. Industrial health. 2007;45(3):497-500.	8
10	Kim JS, Park CR. The Study of Radiation Exposure Reduction by Developing Corpus Striatum Phantom. 방사선기술과학. 2017;40(4):595-603.	1
11	Kim JS. Practical Approach for the Clinical Use of Dopamine Transporter Imaging. Nucl Med Mol Imaging. 2008;42(6):425-34.	2
12	Kim YK, Yoon IY, Kim JM, Jeong SH, Kim KW, Shin YK et al., The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. European Journal of Neurology. 2010;17(3): 487-92.	6
13	Kwon S, Chun K, Kong E, Cho I. Comparison of the Performances of 18F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Nuclear Medicine and Molecular Imaging. 2016;50(3):219-27.	7
14	Lee CY, Choi B, Hwang B, Son MJ, Lee M, Yoo J, et al. Clebopride-Induced Parkinsonism. J Korean Neurol Assoc. 2016;34(3):261-3.	1
15	Lee JY, Yoon EJ, Kim YK, Shin CW, Nam H, Jeong JM, et al. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. J Mov Disord. 2019;12(2):103-12.	7
16	Noh Y, Sung YH, Lee J, Kim EY. Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality. AJNR. 2015;36(11):2010-6.	7
17	Oh ES, Kim JM, Kim YE, Yun JY, Kim JS, Kim SE, et al. The Prevalence of Essential Tremor in Elderly Koreans. J Korean Med Sci. 2014;29(12):1694-8.	6
18	Oh SJ. Radiopharmaceuticals for Neurotransmitter Imaging. Nucl Med Mol Imaging. 2007;41(2):118-31.	2
19	Oh SW, Kim YK, Lee BC, Kim BS, Kim JS, Kim JM, et al. Evaluation of Multiple System Atrophy and Early Parkinson's Disease Using (123I)-FP-CIT SPECT. Nucl Med Mol Imaging. 2009;43(1):10-8.	6
20	Oh YS, Kim JS, Hwang EJ, Lyoo CH. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease. Parkinsonism & related disorders. 2018;56:47-51.	7
21	Park BN, Kim JH, Lee K, Park SH, An YS. Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT. European Radiology. 2015;25(5):1487-96.	1
22	Park HK, Kim JS, Im KC, Oh SJ, Kim MJ, Lee J-H, et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and 18F FP-CIT PET analyses. Movement disorders. 2009;24(2):237-45.	7
23	Sang Eun K, Yearn Seong C, Seung Jun O, Joon Young C, Dae Yoon C, Gyeong Moon K, et al. Pet Imaging of Dopamine Transporters in the Human Brain in Health and Parkinson's Disease with [F-18]β-CIT-FP (초록). 대한핵의학회 춘계학술발표초록집. 1997;1997(0):145.	4
24	Seo M, Oh M, Cho M, Chung SJ, Lee CS, Kim JS. The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nucl Med Mol Imaging. 2014;48(4):287-94.	7
25	Shin S, Kim K, Lee JM, Kim EJ, Kim SJ, Kim IJ, et al. Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease. Journal of clinical neurology. 2019;15(1):102-7.	7
26	Shin, Eun S, Hwang, Onyou, Hwang, Yu S, et al. Enhanced Efficacy of Human Brain-Derived Neural Stem Cells by Transplantation of Cell Aggregates in a Rat Model of Parkinson's Disease. Journal of Korean neurosurgical society. 2014;56(5):383-9.	1
27	Song IU, Kim YD, Cho HJ, Chung SW, Chung YA. An FP-CIT PET Comparison of the Differences in Dopaminergic Neuronal Loss Between Idiopathic Parkinson Disease With Dementia and Without Dementia. Alzheimer disease and associated disorders. 2013;27(1):51-5.	7

연번	서지정보	배제 사유
28	Song YS, Kim JM, Kim KJ, Yun JY, Kim SE. Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease: Comparison With 123I-FP-CIT SPECT. Clinical nuclear medicine. 2017;42(9):675-9.	7
29	Van Der Gucht A, De Langavant Laurent C, Belissant O, Rabu C, Cottureau Anne S, Evangelista E, et al. Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Nuclear Medicine and Molecular Imaging. 2016;50(3):258-60.	6
30	Yang Y, Cheon M, Kwak YT. Is Parkinson's Disease with History of Agent Orange Exposure Different from Idiopathic Parkinson's Disease? Dement Neurocogn Disord. 2016;15(3):75-81.	7
31	Ye-rin K, 김현기, 이교철, 이용진, 박상원, Javeria Z, et al. Comparison of Reconstruction Algorithms for F-18 FP CIT PET Images. The Journal of the Korean Physical Society.2019;74(12):1129-34.	1
32	Yiseul C, Eun Sang L, Jang Woo P, Youn Kyoung J, Mijeong P, Hye Kyung C. Evaluation method based non-invasive imaging in Parkinson's disease models. 한국실험동물학회 학술발표대회 논문집. 2021(7):219.	1
33	Yoon HH, Kim YH, Shin ES, Jeon SR. A Rat Model of Striatonigral Degeneration Generated by Simultaneous Injection of 6-Hydroxydopamine into the Medial Forebrain Bundle and Quinolinic Acid into the Striatum. J Korean Med Sci. 2014;29(11):1555-61.	1
34	Yu AR, Jin Su K, Hee-Joung K, Jisook M, Yun Young C, Joo Hyun K, et al. Assessment of Early Phase F-18-FP-CIT PET as an Alternative Method of FDG PET for Voxel Based Statistical Analysis: Application for Parkinson's Disease Rat Model. IEEE transactions on nuclear science. 2013;60(2):820-3.	1
35	Yu KJ, Lee BJ, Han J, Park D. Usefulness of F-18 FP-CIT PET to predict dopamine-responsive hand tremor in patients other than Parkinson's disease : Two case reports. Medicine. 2018;97(22):10983.	8
36	Yun J-W, Ahn J-B, Kwon E, Ahn JH, Park HW, Heo H, et al. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. 조직공학과 재생의학= Tissue Engineering and Regenerative Medicine. 2016;13(1):100-9.	1
37	강용길, 홍시영. Parkinson's disease에서 [18F]-FP-CIT을 이용한 Brain PET/CT영상의 유용성. 김천대학교 논문집. 2009;30.	2
38	김범산, 장성준, 여재선, 박은경, 김유경, 김종민, et al. 도파민운반체 영상의 파킨슨증 감별진단 성능: (123I)-FP-CIT SPECT 연구. 핵의학분자영상. 2007;41(4):272-9.	6
39	김은미, 김선춘, 정희선, 유영찬. l-디프레닐 투여 후 환위 뇨중 메스암페타민 및 암페타민의 거울상이성질체의 가스크로마토그래피에 의한 분석. 약학회지. 1997;41(6):698-703.	1
40	김재승. 도파민 운반체 영상의 임상이용을 위한 실제적 접근. Nuclear Medicine and Molecular Imaging. 2008;42(6):425-34.	2
41	김정수, 박찬록. 두개골-선조체 팬텀을 이용한 선량 저감화 방안 연구. 방사선기술과학. 2017;40(4):595-603.	1
42	박정미, 유영훈, 안정훈, 이자연, 김지민, 권한별, et al. 파킨슨병 의심 환자에서 18F FP-CIT PET/CT의 임상적 유용성 평가 및 기존진단법과의 비교효과연구. 연구결과보고서. 2016;1(2):1-74.	4
43	배성우, 최홍윤, 위원석, 평진철, 천기정, 강건욱, et al. Spatial Normalization Using Early-Phase [18F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding. Nuclear Medicine and Molecular Imaging. 2020;54(6):305-14.	7
44	배진원, 조재욱, 김대진, 류철형, 이재혁. 신경퇴행성 질환의 전 증상으로 여겨지는 특발성 렘수면 행동 장애 1예. 수면. 2011;8(1):14-6.	7
45	안정훈, 이자연, 김지민, 권한별, 신민경, 류형철, et al. 파킨슨병 의심 환자에서 18F FP-CIT PETCT의 임상적 유용성 평가 및 기존진단법과의 비교효과연구. 연구결과보고서. 2014;1(1):1-55.	4
46	양영순, 천미주, 광용태. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease. Dementia and Neurocognitive Disorders. 2017;16(3):57-63.	7
47	오소원, 김유경, 이병철, 김범산, 김지선, 김종민, et al. 123I-FP-CIT SPECT를 이용한 다중계위측정 및 조기 파킨슨병에서의 평가. Nuclear Medicine and Molecular Imaging. 2009;43(1):10-8.	6
48	오승준. 뇌 신경물질 운반체 영상용 방사성의약품. Nuclear Medicine and Molecular Imaging. 2007;41(2):118-31.	2
49	이강욱, 광범수, 최시완, 강승식, 박기남, 전은석, et al. 심실내 전도장애 환자에서의 99mTc-RBC Gated Blood-Pool Scintigraphy 을 통한 Phase Image Analysis. 핵의학분자영상. 1994;28(1):44-51.	6
50	이선아, 임동규, 김지은, 허재혁. 도파민 영상과 뇌척수액 검사로 진단된 루이소체 치매 1예. 임상노인의학회지. 2016;17(1):42-5.	8

연번	서지정보	배제 사유
51	이선희, 이민, 정유진. 123I-FP-CIT 뇌 단일광자단층촬영. 신의료기술평가 보고서. 2012;1(44):1-113.	4
52	이선희, 이민, 정지영. [18F]FP-CIT 뇌양전자방출단층촬영, 양전자방출전산화단층촬영. 신의료기술평가 보고서. 2012;1(38):1-71.	4
53	이성하, 김한결, 이영건, 류철형, 안성준, 이명식. Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism. Journal of Movement Disorders. 2017;10(1):35-9.	7
54	이재영, 최봄, 황보송, 손명진, 이민우, 유진혁, et al. 클레보프라이드에 의한 파킨슨증. 대한신경과학회지. 2016;34(3):261-3.	7
55	전기평, 나승희. 추체외로 증상이 추가적으로 발생한 알츠하이머치매 환자. 대한임상노인의학회지. 2017;18(2):113-7.	7
56	Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH. Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. Journal of Movement Disorders. 2019;12(2):113-9.	7
57	정유진, 오선영, 박기수, 이찬녕, 박건우, 이재성, et al. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. 핵의학 분자영상. 2013;47(2):73-80.	7
58	최재민, 김경식, 남궁창경, 남기표, 임기천. The Influence of Iteration and Subset on True X method in 18F-FP-CIT Brain Imaging. 대한핵의학기술학회지. 2009;13(4):34-5.	7
59	최재민, 김경식, 남궁창경, 남기표, 임기천. F-18-FPCIP 뇌 영상에서 True-X 재구성 기법을 기반으로 했을 때의 Iteration과 Subset의 영향. 핵의학기술 (대한핵의학기술학회). 2010;14(1):122-6.	7
60	호성희, 송인옥, 정용안. 초기 파킨슨병에서의 Cardiac 123I-Metaiodobenzylguanidine Image를 통한 임상적 예후 평가에 대한 연구(예비연구). 임상노인의학회지. 2016;17(2):74-8.	6
61	홍일기, 김덕윤. PET의 최신지견: F-18 FP-CIT를 이용한 도파민 운반체 영상. 경희의학. 2010;26(1):10-6.	2
국외문헌		
1	Abbasi Gharibkandi N, Hosseini-mehr SJ. Radiotracers for imaging of Parkinson's disease. European Journal of Medicinal Chemistry. 2019;166:75-89.	2
2	Ahn HJ, Yoo WK, Park J, Ma HI, Kim YJ. Cognitive Dysfunction in Drug-induced Parkinsonism Caused by Prokinetics and Antiemetics. Journal of Korean Medical Science. 2015;30(9):1328-33.	7
3	Ahn J, Kim HT, Heo JH. Clinical usefulness of F18-FP-CIT PET/CT in possible dementia with Lewy bodies. Movement Disorders. 2016;31(Supplement 1):S80.	7
4	Ahn JH, Yang HJ, Kim EY, Park JJ, Yoon BN. Dramatic unilateral decrease in uptake via the dopamine transporter: Imaging in a patient with hemiparkinsonism following the lacunar stroke in substantia nigra. Neurology Asia. 2019;24(1):75-8.	4
5	Ahn JY, Heo JH, Kim HT. Clinical usefulness of F18-FP-CIT PET/CT in possible dementia with lewy bodies: Preliminary study. Parkinsonism and Related Disorders. 2016;2:e116.	4
6	An HJ, Seo S, Kang H, Choi H, Cheon GJ, Kim HJ, et al. MRI-Based Attenuation Correction for PET/MRI Using Multiphase Level-Set Method. Journal of Nuclear Medicine. 2016;57(4):587-93.	7
7	An HJ, Seo S, Kang H, Choi H, Cheon GJ, Lee DS, et al. Quantitative evaluation of improved MR-based attenuation correction for brain PET/MRI studies. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2015;56(SUPPL. 3).	4
8	An YS, Yoon JK, Lee SJ, Jeong E, Kim IH. Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image. Clinical Nuclear Medicine. 2019;44(3):e168-e9.	7
9	Anonymous. 9th Convegno Nazionale SINDEM. Journal of Alzheimer's Disease Conference: 9th Convegno Nazionale SINDEM Firenze Italy. 2016;52(Supplement 1).	4
10	Apostolova I, Lange C, Frings L, Klutmann S, Meyer PT, Buchert R. Nigrostriatal Degeneration in the Cognitive Part of the Striatum in Parkinson Disease Is Associated with Frontomedial Hypometabolism. Clinical Nuclear Medicine. 2020;45(2):95-9.	6
11	Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, et al. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. Journal of Nuclear Medicine. 2015;56(2):234-42.	6
12	Arnaldi D, Famà F, Girtler N, Brugnolo A, Pardini M, Mattioli P, et al. Rapid eye movement sleep behavior disorder: a proof-of-concept neuroprotection study for prodromal synucleinopathies. European journal of neurology. 2021;28(4):1210-7.	6

연번	서지정보	배제 사유
13	Arnaldi D, Morbelli S, Brugnolo A, Girtler N, Picco A, Ferrara M, et al. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. <i>Parkinsonism & Related Disorders</i> . 2016;29:47-53.	6
14	Bae S, Choi H, Whi W, Paeng JC, Cheon GJ, Kang KW, et al. Spatial Normalization Using Early-Phase [18F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding. <i>Nuclear Medicine & Molecular Imaging</i> . 2020;54(6):305-14.	7
15	Baek S, Kim J, Oh S, Moon D, Lee J. Aging effects on striatal F-18 FP-CIT binding in normals and hemiparkinsonian patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2:S399-S400.	4
16	Baik K, Chung SJ, Yoo HS, Lee YH, Jung JH, Sohn YH, et al. Sex-dependent association of urate on the patterns of striatal dopamine depletion in Parkinson's disease. <i>European Journal of Neurology</i> . 2020;27(5):773-8.	7
17	Baik K, Lee Y, Chung S, Yoo H, Jung J, Lee P. Relationship between serum uric acid and the pattern of striatal dopamine depletion in de Novo Parkinson's disease. <i>Movement Disorder</i> . 2019;34(Supplement 2):S768.	4
18	Baulieu JL, Aesch-Prunier C. Exploring neurotransmission by brain scan: Contribution to the management of neurodegenerative diseases, today and tomorrow. [French]. <i>Medecine Nucleaire</i> . 2004;28(9):473-81.	4
19	Benaderette S, Fregonara PZ, Apartis E, Nguyen C, Trocello JM, Remy P, et al. Psychogenic parkinsonism: A combination of clinical, electrophysical, and [123I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. <i>Movement Disorders</i> . 2006;21(3):310-7.	6
20	Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2010;37(3):537-44.	6
21	Bonfante JAF, Pagano G, Politis M. Neuroimaging studies in familial forms of Parkinson's disease: A systematic review. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):507.	4
22	Booij J, De Jong J, De Bruin K, Knol R, De Win MML, Van Eck-Smit BLF. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. <i>Journal of nuclear medicine</i> . 2007;48(3):359-66.	6
23	Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. <i>Journal of neurology, neurosurgery, and psychiatry</i> . 1997;62(2):133-40.	6
24	Buchholz HG, Rosar F, Hoffmann M, Schreckenberger M. Impact of reference databases on evaluation of 123I-FP-CIT striatal binding: a comparison between Hermes EARL-BRASS and GE DaTQuant. <i>Journal of nuclear medicine</i> . 2020;61.	4
25	Carey G, Gormezoglu M, de Jong JJA, Hofman PAM, Backes WH, Dujardin K, et al. Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review. <i>Movement Disorders</i> . 2021;36(2):327-39.	2
26	Carrillo Garcia F. Parkinson's disease and other parkinsonisms: diagnostic protocol. <i>Medicine (Spain)</i> . 2019;12(73):4313-5.	7
27	Cascianelli S, Tranfaglia C, Fravolini ML, Bianconi F, Minestrini M, Nuvoli S, et al. Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using 123I-FP-CIT brain SPET data by using an artificial neural network classifier, a classification tree (CIT). <i>Hellenic journal of nuclear medicine</i> . 2017;20:165.	6
28	Chaly T, Dhawan V, Kazumata K, Antonini A, Margoueff C, Dahl JR, et al. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. <i>Nuclear Medicine and Biology</i> . 1996;23(8):999-1004.	7
29	Choi BW, Kang S, Kim HW, Kwon OD, Vu HD, Youn SW. Faster Region-Based Convolutional Neural Network in the Classification of Different Parkinsonism Patterns of the Striatum on Maximum Intensity Projection Images of [18F]FP-CIT Positron Emission Tomography. <i>Diagnostics</i> . 2021;11(9):28.	7
30	Choi EG, Lee WC, Shin JY, Seo JS, Lee CS. Novel compound heterozygous mutations of PLA2G6 in a Korean pedigree of young-onset Parkinson's disease: A study of whole genome sequencing. <i>Parkinsonism and Related Disorders</i> . 2016;2:e168-e9.	4

연번	서지정보	배제 사유
31	Choi EJ, Gu JK, Lee DG, Kim SM, Lee JK, Lee CS. Improvement of impulse control disorder in Parkinson's disease patients treated with subthalamic nucleus stimulation. Movement Disorders. 2016;31(Supplement 2):S19.	4
32	Choi H, Cheon GJ, Kim HJ, Choi SH, Kim YI, Kang KW, et al. Gray matter correlates of dopaminergic degeneration in Parkinson's disease: A hybrid PET/MR study using (18) F-FP-CIT. Human Brain Mapping. 2016;37(5):1710-21.	7
33	Choi H, Cheon GJ, Kim HJ, Choi SH, Lee JS, Kim YI, et al. Segmentation-based MR attenuation correction including bones also affects quantitation in brain studies: An initial result of 18F-FP-CIT PET/MR for patients with parkinsonism. Journal of Nuclear Medicine. 2014;55(10):1617-22.	7
34	Choi JY, Lee MK, Cho WG, Lyoo CH, Lee KC, Ryu YH. Correlation of dopaminergic and serotonergic dysfunction in a rat model of parkinson's disease. Journal of Cerebral Blood Flow and Metabolism. 2016;36(Supplement 1):683-4.	4
35	Choi N, Park KW, Hong SH, Lee CS. Postural and kinetic tremor is associated with pallidal dopamine denervation in patients with Parkinson's disease. Movement Disorder. 2019;34(Supplement 2):S782.	4
36	Choi S, Shin C, Ahn TB. Bilateral stereotypy after unilateral cerebellar infarction. Acta Neurologica Belgica. 2019;119(3):483-5.	2
37	Chun K, Kong E, Cho I. Comparison of perfusion 18F-FP-CIT PET and 99mTc-ECD SPECT in parkinsonian disorders. Medicine. 2021;100(34):e27019.	7
38	Chun KA, Kong E, Cho I. An Incidental Finding of Skull Hemangioma During 18F-FP CIT Brain PET/CT. Clinical Nuclear Medicine. 2015;40(10):e488-9.	8
39	Chun MH, Kang CG, Kong EJ, Chang MC. Parkinsonism after external ventricular drainage in a patient with intraventricular hemorrhage. Journal of Stroke & Cerebrovascular Diseases. 2015;24(3):e75-8.	8
40	Chung EJ, Hwang JH, Lee MJ, Hong JH, Ji KH, Yoo WK, et al. Expansion of the clinicopathological and mutational spectrum of Perry syndrome. Parkinsonism & Related Disorders. 2014;20(4):388-93.	7
41	Chung M, Park YS, Kim JS, Kim YJ, Ma HI, Jang SJ, et al. Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET. Japanese Journal of Radiology. 2015;33(10):609-18.	7
42	Chung SJ. Subcortical and brainstem hemiatrophy accompanied by iron deposition in a patient with hemiparkinsonism-hemiatrophy syndrome: a case report. BMC Neurology. 2021;21(1) (no pagination)(51).	8
43	Chung SJ, Lee HS, Yoo HS, Lee YH, Lee PH, Sohn YH. Patterns of striatal dopamine depletion in early Parkinson disease: Prognostic relevance. Neurology. 2020;95(3):e280-e90.	7
44	Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH. Does the pattern of striatal dopamine depletion contribute nonmotor symptoms in Parkinson's disease? Movement Disorders. 2015;1):S152-S3.	4
45	Chung SJ, Lee S, Yoo HS, Baik K, Lee HS, Jung JH, et al. Different patterns of beta-amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. Neurobiology of Aging. 2021;101:199-206.	7
46	Chung SJ, Lee S, Yoo HS, Lee YH, Lee HS, Choi Y, et al. Association of the Non-Motor Burden with Patterns of Striatal Dopamine Loss in de novo Parkinson's Disease. Journal of Parkinsons Disease Print. 2020;10(4):1541-9.	7
47	Chung SJ, Lee YH, Yoo HS, Sohn YH, Ye BS, Cha J, et al. Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies. European Journal of Nuclear Medicine & Molecular Imaging. 2019;46(8):1652-60.	7
48	Chung SJ, Park YH, Yun HJ, Kwon H, Yoo HS, Sohn YH, et al. Clinical relevance of amnesic versus non-amnesic mild cognitive impairment subtyping in Parkinson's disease. European Journal of Neurology. 2019;26(5):766-73.	7
49	Chung SJ, Ryu HS, Oh JS, Park KW, Lee C, You S, et al. Distinct clinical features of predominant pre-synaptic and transsynaptic nigrostriatal dysfunction in multiple system atrophy. Neurology Conference: 71st Annual Meeting of the American Academy of Neurology, AAN. 2019;92(15 Supplement 1).	4

연번	서지정보	배제 사유
50	Chung SJ, Sohn YH, Ye BS, Cha J, Lee PH. Distinct Fp-Cit Pet Patterns of Alzheimer's Disease with Parkinsonism and Dementia with Lewy Bodies. <i>Alzheimer's and Dementia</i> . 2019;15(7 Supplement):P1538.	4
51	Chung SJ, Yoo HS, Lee HS, Oh JS, Kim JS, Sohn YH, et al. The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in de Novo Parkinson Disease. <i>Clinical Nuclear Medicine</i> . 2018;43(11):787-92.	7
52	Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH. Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. <i>Journal of Movement Disorders</i> . 2019;12(2):113-9.	7
53	Chung SJ, Yoo HS, Lee YH, Sohn YH, Ye BS, Cha J, et al. Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. <i>Parkinsonism & Related Disorders</i> . 2020;81:140-3.	7
54	Chung SJ, Yoo HS, Moon H, Oh JS, Kim JS, Park YH, et al. Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2018;89(2):169-74.	7
55	Chung SJ, Yoo HS, Oh JS, Kim JS, Ye BS, Sohn YH, et al. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. <i>Parkinsonism & Related Disorders</i> . 2018;51:43-8.	7
56	Chung YA, Song IU. Dual Time Point F-18 FP-CIT PET Imaging in Idiopathic Parkinson's disease. <i>Movement Disorders</i> . 2016;31(Supplement 1):S85.	4
57	Cilia R, Marotta G, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced Parkinsonism. <i>Movement Disorders</i> . 2014;1):S68-S9.	4
58	Cilia R, Righini A, Marotta G, Benti R, Marconi R, Isaias IU, et al. Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. <i>European Journal of Neurology</i> . 2007;14(8):944-6.	7
59	Cocciolillo F, Di Giuda D, Annunziata S, Scolozzi V, Bove F, Vita MG, et al. Difference in striatal dopamine transporter availability and psychiatric symptoms in Parkinson's disease subtypes: 123I-FP-CIT SPECT results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S571-S2.	4
60	Cocciolillo F, Di Giuda D, Bove F, Vita MG, Piano C, Bentivoglio AR, et al. Striatal dopamine transporter availability in Parkinson's disease subtypes: 123I-FP-CIT SPECT results. <i>Clinical and Translational Imaging</i> . 2017;5(Supplement 1):S117.	4
61	Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. <i>European journal of nuclear medicine and molecular imaging</i> . 2005;32(10):1176-85.	6
62	Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, et al. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. <i>Clinical neuropharmacology</i> . 2004;27(3):111-5.	6
63	Delva A, Van Weehaeghe D, van Aalst J, Ceccarini J, Koole M, Baete K, et al. Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2020;47(8):1913-26.	6
64	Derlin T, Afzal W, Wilke F, Apostolova I, Klutmann S, Meyer PT, et al. IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement. <i>Nuclear-Medizin</i> . 2010;49(4):139-47.	6
65	Dodel RC, Hoffken H, Moller JC, Bornschein B, Klockgether T, Behr T, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. <i>Movement Disorders</i> . 2003;18 Suppl 7:S52-62.	6
66	Eggers C, Schwartz F, Pedrosa DJ, Kracht L, Timmermann L. Parkinson's disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum. <i>PLoS ONE [Electronic Resource]</i> . 2014;9(5):e96629.	6
67	El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, et al. Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. <i>European journal of nuclear medicine and molecular imaging</i> . 2006;33(1):87-92.	6

연번	서지정보	배제 사유
68	Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2009;36(3):454-62.	6
69	Euctr FR. Study to demonstrate an at least equivalent performance of a new test in brain imaging test compared to the reference examination to establish the differential diagnosis between Parkinson's Disease and Essential Tremor. https://trialsearchwho.int/Trial2.aspx?TrialID=EUCTR2019-000247-27-FR . 2019.	4
70	Euctr GB. An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial. https://trialsearchwho.int/Trial2.aspx?TrialID=EUCTR2009-018137-37-GB . 2010.	4
71	Fernandez Bonfante J, Pagano G, Politis M. Neuroimaging studies in familial forms of Parkinson's disease: A systematic review. <i>Movement Disorders</i> . 2017;32(Supplement 2):680.	4
72	Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. <i>Nuclear medicine communications</i> . 2006;27(4):381-6.	6
73	Frings L, Heimbach B, Meyer PT, Hellwig S. Intrinsic Alertness Is Impaired in Patients with Nigrostriatal Degeneration: A Prospective Study with Reference to [123I]FP-CIT SPECT and [18F]FDG PET. <i>Journal of Alzheimer's Disease</i> . 2020;78(4):1721-9.	6
74	Gerasimou GP, Aggelopoulou TC, Costa DC, Gotzamani-Psarrakou A. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders. <i>Nuclear Medicine Review</i> . 2006;9(2):147-53.	2
75	Glockler T, Junghanns S. Biomarkers for early diagnosis of Parkinson's disease. [German]. <i>Nervenheilkunde</i> . 2005;24(1):9-13.	3
76	Hammes J, Bischof GN, Drzezga A. Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases. <i>Clinical and Translational Imaging</i> . 2017;5(5):465-71.	7
77	Hammes J, Tittgemeyer M, Eggers C, Drzezga A, Van Eimeren T. F-18-DOPA-PET predicts impulsive behavior under dopaminergic therapy in Parkinson patients. <i>NuklearMedizin</i> . 2017;56(2):A24-A5.	4
78	Han I, Park Y, Chung HM, Moon JS, Chung S. Planning clinical trial of stem cells in patients with parkinson's disease. <i>Stereotactic and Functional Neurosurgery</i> . 2013;1):187.	4
79	Han S, Lee IJ, Oh M, Oh J, Lee SJ, Oh SJ, et al. [18F]FP-CIT PET evidence that pure akinesia with gait freezing is a phenotypic spectrum of progressive supranuclear palsy. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2015;56(SUPPL. 3).	4
80	Han S, Oh M, Oh JS, Lee SJ, Oh SJ, Chung SJ, et al. Subregional Pattern of Striatal Dopamine Transporter Loss on 18F FP-CIT Positron Emission Tomography in Patients With Pure Akinesia With Gait Freezing. <i>JAMA Neurology</i> . 2016;73(12):1477-84.	7
81	Hansen A, Damholdt M, Knudsen K, Fedorova T, Ostergaard K, Brooks D, et al. 18F-AV-1451 PET imaging in pre-dementia Parkinson's disease. <i>Movement Disorders</i> . 2017;32(Supplement 2):1013-4.	4
82	Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. <i>Brain</i> . 2016;139(7):2039-49.	6
83	Hartmann A, Mullner J, Meier N, Hesekamp H, Van Meerbeeck P, Habert MO, et al. Bee venom for the treatment of Parkinson disease - A randomized controlled clinical trial. <i>Plos one</i> . 2016;11(7) (no pagination).	7
84	Heo JH, Won HY. Application of F18-FP-CIT PET/CT in possible dementia with lewy bodies. <i>Neurodegenerative Diseases</i> . 2017;17(Supplement 1):1522.	4
85	Hering R, Strauss KM, Tao X, Bauer A, Voitalla D, Mietz EM, et al. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). <i>Human Mutation</i> . 2004;24(4):321-9.	7
86	Herzog H, Langen KJ, Weirich C, Rota Kops E, Kaffanke J, Tellmann L, et al. High resolution BrainPET combined with simultaneous MRI. [German]. <i>NuklearMedizin</i> . 2011;50(2):74-82.	3
87	Hickey PT, Kuchibhatla M, Scott B, Gauger L, Stacy MA. Dopamine transporter imaging has no impact on functional outcomes in de novo probable Parkinson's disease. <i>Journal of parkinson's disease</i> . 2017;7(2):279-87.	6

연번	서지정보	배제 사유
88	Hickey PT, Kuchibhatla M, Scott BL, Gauger L, Stacy MA. Assessment of outcomes in Parkinson's disease subjects randomized to SPECT imaging of the dopamine transporter. Movement disorders. 2015;30:S381-S2.	4
89	Hong CM, Ryu HS, Ahn BC. Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism. American Journal of Nuclear Medicine and Molecular Imaging. 2018;8(6):360-72.	2
90	Hong JY, Chung SJ, Lee JE, Sunwoo MK, Lee PH, Sohn YH. Predictive value of the smell identification test for nigrostriatal dopaminergic depletion in Korean tremor patients. Parkinsonism and Related Disorders. 2013;19(11):1018-21.	7
91	Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. 2014;82(18):1597-604.	7
92	Hong JY, Sunwoo MK, Oh JS, Kim JS, Sohn YH, Lee PH. Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging. PLoS ONE [Electronic Resource]. 2016;11(6):e0157410.	7
93	Honkanen E, Kemppainen N, Noponen T, Seppanen M, Joutsa J, Kaasinen V. Bupropion causing misdiagnosis in brain dopamine transporter imaging for parkinsonism. Movement Disorders. 2018;33(Supplement 2):S650-S1.	4
94	Honkanen EA, Kemppainen N, Noponen T, Seppanen M, Joutsa J, Kaasinen V. Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism. Clinical Neuropharmacology. 2019;42(5):181-3.	6
95	Horimoto Y, Hayashi E, Ito Y, Iida A, Hibino H, Inagaki A, et al. Dopaminergic performances in patients with parkinsonism—a combination study of dopamine transporter SPECT, dopamine synthesis and receptor pet. Journal of the Neurological Sciences. 2017;381(Supplement 1):257.	4
96	Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson's disease. Brain. 2007;130(Pt 7):1834-46.	7
97	Hughes SJ. Nuclear medicine functional imaging of the brain. Clinical Medicine, Journal of the Royal College of Physicians of London. 2012;12(4):364-8.	7
98	Hwang D, Kim KY, Kang SK, Seo S, Paeng JC, Lee DS, et al. Improving the Accuracy of Simultaneously Reconstructed Activity and Attenuation Maps Using Deep Learning. Journal of Nuclear Medicine. 2018;59(10):1624-9.	7
99	Hwang I, Ha SW, Yang Y, Kim SM. Hydrocephalus in Patient with Multiple System Atrophy: Innocent Bystander or Guilty Party? Dementia and Neurocognitive Disorders. 2016;15(2):49-51.	8
100	Hwangbo S, Hong Y, Choi SW, Kim JY, Han YM, Kang SY. Early- and late-phase 18F-FP-CIT PET images in vascular parkinsonism due to midbrain infarct. Neurological Sciences. 2019;40(5):1089-91.	8
101	Iacozzi M, Piccardo A, Puntoni M, Morbelli S, Marinelli L, Abruzzese G, et al. Direct correlation between cardiac and striatal 18F-DOPA uptake in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging. 2012;2):S183-S4.	4
102	Im HJ, Hwang DW, Lee HK, Jang J, Lee S, Youn H, et al. In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease. Molecular Imaging. 2013;12(4):224-34.	1
103	Im HJ, Hwang DW, Lee HK, Kim YS, Youn H, Lee DS. In vivo bioluminescence imaging of transplanted neural stem cells in mouse model of parkinson's disease. Molecular Imaging and Biology. 2010;2):S1607.	4
104	Jakobson Mo S, Axelsson J, Jonasson L, Larsson A, Ogren MJ, Ogren M, et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison. EJNMMI Research. 2018;8(1):100.	6
105	Jang H, Jang YK, Park S, Kim SE, Kim SJ, Cho SH, et al. Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study. Neurobiology of Aging. 2020;86:75-80.	7
106	Jang W, Lee JY, Kim JY, Lee SJ, Kim TY, Choi YY, et al. Intrasubject relationship between striatal 18F-FP-CIT uptake and cardiac 123I-MIBG uptake differs by motor subtype in early Parkinson disease. Medicine. 2021;100(33):e26995.	7

연번	서지정보	배제 사유
107	Jang W, Park J, Shin KJ, Kim JS, Kim JS, Youn J, et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. Journal of the neurological sciences. 2014;337(1-2):47-54.	7
108	Jang W, Youn J. Could autophagy-related proteins be a biomarker in early Parkinson's disease? Potential novel CSF biomarkers in Parkinson's disease. Parkinsonism and Related Disorders. 2018;46(Supplement 2):e65.	4
109	Jeon B. Imaging of RBD: New MRI and spect data. Journal of the Neurological Sciences. 2019;405(Supplement):48.	4
110	Jeong E, Oh SY, Pahk K, Lee CN, Park KW, Lee JS, et al. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. Nuclear Medicine & Molecular Imaging. 2013;47(2):73-80.	7
111	Jeong H, Chung S, Oh J, Kim J, Lee P. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. Movement Disorders. 2018;33(Supplement 2):S563.	4
112	Jeong SH, Chung SJ, Yoo HS, Hong N, Jung JH, Baik K, et al. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease. Brain. 2021;144(4):1127-37.	7
113	Jeong YJ, Cheon SM, Kang DY, Kim JW. F-18 FP-CIT PET in Multiple System Atrophy of the Cerebellar Type: Additional Role in Treatment. Contrast Media & Molecular Imaging. 2017;2017:8598705.	7
114	Jeong YJ, Jeong JE, Cheon SM, Yoon BA, Kim JW, Kang DY. Relationship between the washout rate of I-123 MIBG scans and autonomic function in Parkinson's disease. PLoS ONE [Electronic Resource]. 2020;15(3):e0229860.	6
115	Jeong YJ, Kang DY, Yoon HJ. Perfusion and DAT analysis for depressive mood in drug naive PD patients using dual phase F-18 FP-CIT PET. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2017;58(Supplement 1).	4
116	Jeong YJ, Son HJ, Yoon HJ, Kang DY. Functional volumetric analysis of striatum using F-18 FP-CIT PET in patients with idiopathic Parkinson's disease and normal subjects. Annals of Nuclear Medicine. 2016;30(8):572-8.	7
117	Jeong YJ, Son HJ, Yoon HJ, Kang DY. Metabolic striatal volume analysis using isocontour VOI method in F-18 FP-CIT PET. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2016;57(SUPPL. 2).	4
118	Jin S, Chung SJ, Lee C, Oh M, Oh J, Lee IJ, et al. Feasibility of earlyphase 18F-FP-CIT PET image for differential diagnosis of atypical parkinsonism: Preliminary study. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2015;56(SUPPL. 3).	4
119	Jin S, Oh M, Oh SJ, Chung SJ, Lee CS, Kim JS. Differential diagnosis of parkinsonism using dual-phase F-18 FP-CIT PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2012;2):S435-S6.	4
120	Jin S, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clinical Nuclear Medicine. 2017;42(2):e80-e7.	7
121	Jo KD, Jang W, Kim JE, Lee MK. Unilateral parkinsonism in a patient with secondary moyamoya syndrome. Journal of the Neurological Sciences. 2017;381(Supplement 1):610.	4
122	Jprn U. A comparative randomized study for the evaluation of the overlaying effect of Selegiline or Zonisamide over Levodopa in Parkinson's disease. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000022533 . 2016.	4
123	Ju H, Lee EJ, Lee M, Kwon KY. Early suspicion of progressive supranuclear palsy using dopamine transporter imaging: an illustrative case presenting with levodopa-responsive parkinsonism. Neurological Sciences. 2021;42(8):3435-7.	2
124	Kang K, Choi D, Lee HW. Unusual idiopathic normal pressure hydrocephalus patient with marked asymmetric and upper body parkinsonism. Annals of Indian Academy of Neurology. 2016;19(2):245-8.	8
125	Kang SW, Jeon S, Yoo HS, Chung SJ, Lee PH, Sohn YH, et al. Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. Neurology. 2019;92(17):e2015-e26.	7

연번	서지정보	배제 사유
126	Kasanuki K, Iseki E, Ota K, Kondo D, Ichimiya Y, Sato K, et al. 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2017;44(3):358-65.	7
127	Kasanuki K, Iseki E, Ota K, Kondo D, Suzuki M, Ichimiya Y, et al. Utility of 123I-FP-CIT SPECT for early diagnosis of dementia with lewy bodies: Correlation between 123I-FP-CIT SPECT findings and clinical symptoms. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1):123.	4
128	Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. <i>Journal of Nuclear Medicine</i> . 1998;39(9):1521-30.	7
129	Kct. A clinical study to determine the optimal dose of WIN-1001X by evaluating its efficacy and safety in patients with early Parkinson's disease. https://trialsearchwho.int/Trial2.aspx?TrialID=KCT0004536 . 2019.	4
130	Kemp PM. Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia. <i>Nuclear Medicine Communications</i> . 2005;26(2):87-96.	2
131	Kim A, Kim HJ, Jeon B. Importance of proper window setting in visual assessment of dopamine transporter imaging: A case of early-onset parkinsonism related to Park2 gene mutation. <i>Neurology Asia</i> . 2016;21(2):187-9.	8
132	Kim A, Kim HJ, Jeon BS. Importance of proper window setting on visual assessment of dopamine transporter image. <i>Movement Disorders</i> . 2015;1):S13.	4
133	Kim C, Kim DY, Hong K. Vascular Parkinsonism by Infarctions at Different Locations on 18F-FP-CIT PET/CT. <i>Clinical Nuclear Medicine</i> . 2019;44(11):E627-E8.	7
134	Kim DH, Kyeong S, Cheon M, Ha SW, Yoo J, Kim SM. Characterization of idiopathic Parkinson's disease subgroups using quantitative gait analysis and corresponding subregional striatal uptake visualized using 18F-FP-CIT positron emission tomography. <i>Gait & Posture</i> . 2020;82:167-73.	7
135	Kim EY. Imaging approaches to parkinsonism. <i>Neuroradiology</i> . 2018;60(1 Supplement 1):74-5.	4
136	Kim H, Kim J, Oh J. Different loss of dopamine transporter according to metabolic subtypes of multiple system atrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S276.	4
137	Kim H, O JH, Park H, Han EJ, Park YH. Correlation between F-18 FDG FP-CIT and clinical findings in patients with parkinson's disease. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	4
138	Kim H, Oh M, Oh JS, Moon H, Chung SJ, Lee CS, et al. Association of striatal dopaminergic neuronal integrity with cognitive dysfunction and cerebral cortical metabolism in Parkinson's disease with mild cognitive impairment. <i>Nuclear Medicine Communications</i> . 2019;40(12):1216-23.	7
139	Kim HJ, Suh M, Cheon GJ, Kim JY, Lee JY, Jin JY, et al. Initial 18F-FP-CIT PET in patients with Parkinsonism can predict differential diagnosis reassessed after minimum 3 years of follow-up. <i>Clinical Autonomic Research</i> . 2018;28(1):156-7.	4
140	Kim HS, Oh SH, Kim WC, Kim OJ, Jang SJ. Cognitive impairment as another possible cause of scan without evidence of dopaminergic deficit (SWEDD) patients. <i>Movement Disorders</i> . 2013;1):S303.	4
141	Kim HW, Kim JS, Oh M, Oh JS, Lee SJ, Oh SJ, et al. Different loss of dopamine transporter according to subtype of multiple system atrophy. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2016;43(3):517-25.	7
142	Kim J, Kim JS, Oh SJ, Kim SJ, You S, Aarsland D, et al. Comparison of [18F]FDG-PET findings in PIB(+) Lewy body dementia, PIB(-) Lewy body dementia and Alzheimer disease. <i>Movement Disorders</i> . 2010;3):S720-S1.	4
143	Kim J, Lee MS. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2018;46(Supplement 2):e15.	4
144	Kim J, Lee S. A patient with Niemann-Pick type C presenting with dopaminergic deficit. <i>Journal of the Neurological Sciences</i> . 2015;1):e274.	4
145	Kim JS, Cho H, Choi JY, Lee SH, Ryu YH, Lyoo CH, et al. Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. <i>PLoS ONE [Electronic Resource]</i> . 2015;10(7):e0132585.	5
146	Kim JS, Cho JW, Youn J. The association between motor laterality and cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> . 2017;32(Supplement 2):629.	4

연번	서지정보	배제 사유
147	Kim JS, Oh YS, Kim YI, Yang DW, Chung YA, You IR, et al. Combined use of 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): A 2-year follow-up study. Archives of Gerontology and Geriatrics. 2013;56(1):124-8.	7
148	Kim JY, Lee SJ, Choi YY, Kim HT. Relationship of F-18 FP-CIT dopamine transporter loss & cardiac I-123 MIBG uptake is different between the subtypes of Parkinson's diseases. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2017;58(Supplement 1).	4
149	Kim KH, Seo JD, Kim ES, Kim HS, Jeon S, Pak K, et al. Comparison of Amyloid in Cerebrospinal Fluid, Brain Imaging, and Autopsy in a Case of Progressive Supranuclear Palsy. Alzheimer Disease and Associated Disorders. 2020;34(3):275-7.	7
150	Kim M, Kyu PJ, Seunghwan M, Hyeon AJ, Sun KJ, Whan CJ, et al. Asymmetric dopaminergic depletion is related with cardiovascular non-motor symptom in drug-naive patients with Parkinson's disease. Journal of Parkinson's Disease. 2019;9(1):169.	4
151	Kim MJ, Kim JS, You S, Kim YJ, Kim SR, Chung SJ. Pre- and post-synaptic dopaminergic dysfunction in multiple system atrophy: Combined [18F]FP-CIT and [18F]FDG-PET study. Journal of Parkinson's Disease. 2013;1):80.	4
152	Kim SJ, Lee C. [18F]FDG PET and [18F]FP-CIT PET studies in atypical parkinsonism. Movement Disorders. 2014;2):S89.	4
153	Kim Y, Kim JS, Kim SJ, Kim SR, Kim J, You S, et al. [18F]FP-CIT PET and [18F]FDG PET findings in PD patients with impulse control disorder. Movement Disorders. 2011;2):S246.	4
154	Kim Y, Shin J, Lee J, Shin S, Nam H, Kim H, et al. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(SUPPL 1):S625-S6.	4
155	Kim YI, Im HJ, Paeng JC, Lee JS, Eo JS, Kim DH, et al. Validation of simple quantification methods for 18F-FP-CIT PET using automatic delineation of volumes of interest based on statistical probabilistic anatomical mapping and isocontour margin setting. Nuclear Medicine and Molecular Imaging. 2012;46(4):254-60.	7
156	Kim YJ, Lyoo CH, Hong S, Kim NY, Lee MS. Neuroimaging studies and whole exome sequencing of PLA2G6-associated neurodegeneration in a family with intrafamilial phenotypic heterogeneity. Parkinsonism & Related Disorders. 2015;21(4):402-6.	7
157	Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Movement Disorders. 2006;21(10):1724-7.	7
158	Knol RJJ, de Bruin K, de Jong J, van Eck-Smit BLF, Booij J. In vitro and ex vivo storage phosphor imaging of short-living radioisotopes. Journal of Neuroscience Methods. 2008;168(2):341-57.	7
159	Knudsen K, Fedorova TD, Horsager J, Andersen KB, Skjaerbaek C, Berg D, et al. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. Journal of Parkinsons Disease Print. 2021;11(4):1677-87.	6
160	Ko J, Lee C, Eidelberg D. Striatal dopamine transporter integrity vs. whole-brain disease-related glucose metabolic patterns in parkinsonisms. Journal of Cerebral Blood Flow and Metabolism. 2016;36(Supplement 1):193-4.	4
161	Ko JH, Katako A, Aljuaid M, Goertzen AL, Borys A, Hobson DE, et al. Distinct brain metabolic patterns separately associated with cognition, motor function, and aging in Parkinson's disease dementia. Neurobiology of Aging. 2017;60:81-91.	7
162	Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. Journal of nuclear medicine. 2005;46(7):1109-18.	6
163	Kong Y, Zhang C, Liu K, Wagle Shukla A, Sun B, Guan Y. Imaging of dopamine transporters in Parkinson disease: a meta-analysis of 18 F/123 I-FP-CIT studies. Annals of Clinical & Translational Neurology. 2020;7(9):1524-34.	2
164	Korsholm K, Anderberg L, Lonsdale M, Broedsgaard E, Denholt C, Madsen J, et al. A back-to-back comparison of 18F-FE-PE2I-PET/CT and 123I-FP-CIT-SPECT dopamine transport imaging in the diagnostic work-up of patients with clinical features of parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging. 2018;45(Supplement 1):S399.	4

연번	서지정보	배제 사유
165	Krenn Y, Fischer P. Dementia with Lewy Bodies (DLB). [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2006;7(1):32-42.	3
166	Kwon DY, Park MH, Park K, Song MH, Lee Y. Substantia nigral signal change of neuromelanin-sensitive T1-weighted magnetic resonance imaging in patients with F-18-FPCIT positron emission tomography confirmed drug-induced Parkinsonism. Movement Disorders. 2013;1):S48.	4
167	Kwon GH, Jang J, Choi HS, Hwang EJ, Jung SL, Ahn KJ, et al. The phase value of putamen measured by susceptibility weighted images in Parkinson's disease and in other forms of Parkinsonism: A correlation study with F18 FP-CIT PET. Acta Radiologica. 2016;57(7):852-60.	7
168	Kwon HN, Ryu HS, Park YJ, Kim MS, Park KW, Kim SR, et al. Ethnicity-specific clinical and neuroimaging characteristics in multiple system atrophy. Neurology Conference: 70th Annual Meeting of the American Academy of Neurology, AAN. 2018;90(15 Supplement 1).	4
169	Kwon KY. Distinct pattern of striatal dopaminergic depletion in patients with parkin mutation. Movement Disorders. 2017;32(Supplement 2):1002-3.	4
170	Kwon KY, Koh SB. A pilot study of F-18 FP-CIT PET imaging in early-onset patients with parkinson's disease: Parkin versus non-parkin mutation. NeuroQuantology. 2018;16(1):52-6.	7
171	Kwon S, Chun K, Kong E, Cho I. Comparison of the Performances of (18)F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Nuclear Medicine & Molecular Imaging. 2016;50(3):219-27.	7
172	Kwon SH, Yoon JH, Yoon JK, Lee SJ, Jo KS, Lee DH, et al. Correlation between F-18 FP-CIT PET and cardiac I-123 MIBG uptake in parkinson's disease. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2015;56(SUPPL. 3).	7
173	Lee C, Lee J, Koo JM, Kim S, Kim SM, Doudet D. Pet evidence for distinct features of tau parkinsonism and parkinsonism with alpha-synucleinopathy. Neurology Conference: 67th American Academy of Neurology Annual Meeting, AAN. 2015;84(SUPPL. 14).	4
174	Lee C, Park K, Choi N, Kim S, Ko J, Doudet D. Topographical subtypes of multiple system atrophy: MRI and PET studies. Movement Disorders. 2020;35(SUPPL 1):S492-S3.	4
175	Lee C, Ryu HS, Oh M, Oh JS, Moon H, Won Park K, et al. Pre- and post-synaptic dopaminergic dysfunction and clinical features in cerebellar type of multiple system atrophy. Neurology Conference: 69th American Academy of Neurology Annual Meeting, AAN. 2017;88(16 Supplement 1).	4
176	Lee CS. Rationale of STN-DBS in early stage of motor fluctuations in patients with Parkinson's disease. Neuromodulation. 2011;14(2):197.	4
177	Lee CS, Kim SJ, Kim JS. Striatal [18F]FDG uptake decreased only after a substantial loss of striatal [18F]FP-CIT binding in patients with multiple system atrophy: Evidence for linked neurodegeneration. Movement Disorders. 2013;1):S274-S5.	4
178	Lee CS, Kim SJ, Oh SJ, Kim HO, Yun SC, Doudet D, et al. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease. Annals of Nuclear Medicine. 2014;28(9):874-9.	7
179	Lee CS, Park SY, Oh SH, Kim SJ, Kim JS, Cho ZH. Neuroimaging correlates of clinical phenotypes in multiple system atrophy: MR DTI and PET studies using [18F]FP-CIT and [18F]FDG. Movement Disorders. 2012;1):S244.	4
180	Lee CS, You SY, You CG, Kim KA, Kim JS. Effects of aging on [18F]FP-CIT PET measures in normal subjects and PD patients. Movement Disorders. 2010;2):S386.	4
181	Lee D, Na BS, Hong IK, Ahn TB. Parkinsonism in Spinocerebellar ataxia type 7. Journal of the Neurological Sciences. 2016;365:151-3.	2
182	Lee DH, Sohn YH, Lee PH. A analysis study of olfactory function in patients with de novo idiopathic Parkinson's disease patients. Movement Disorders. 2014;1):S383-S4.	4
183	Lee DY, Oh M, Kim SJ, Oh JS, Chung SJ, Kim JS. Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease. Clinical Nuclear Medicine. 2019;44(11):855-9.	7
184	Lee H, Baek SY, Kim EJ, Huh GY, Lee JH, Cho H. MRI T_2^* and T_2^* relaxometry to visualize neuromelanin in the dorsal substantia nigra pars compacta. Neurolmage. 2020;211 (no pagination)(116625).	7

연번	서지정보	배제 사유
185	Lee H, Hwang KH. Midbrain 18F-FP-CIT uptake in evaluation of parkinsonism. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2018;59(Supplement 1).	4
186	Lee HD, Chang MC. Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report. Medicine (United States). 2017;96(50) (no pagination)(e9195).	8
187	Lee I, Kim JS, Park JY, Byun BH, Park SY, Choi JH, et al. Head-to-head comparison of 18 F-FP-CIT and 123 I-FP-CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study. Synapse. 2018;72(7):e22032.	7
188	Lee J. Early postural instability is an effective predictor of future freezing of gait in Parkinson's disease. Movement Disorder. 2019;34(Supplement 2):S382.	4
189	Lee J, Kim GS. Comparative analysis of cognitive function between unilaterally and bilaterally affected Parkinson's disease. Movement Disorders. 2020;35(SUPPL 1):S175.	4
190	Lee JJ, Oh JS, Ham JH, Lee DH, Lee I, Lee PH, et al. Gender difference in depletion of presynaptic nigrostriatal dopamine in de novo Parkinson's disease. Movement Disorders. 2015;1):S14.	4
191	Lee JJ, Oh JS, Ham JH, Lee DH, Lee I, Sohn YH, et al. Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease. Neurobiology of Aging. 2016;38:197-204.	7
192	Lee JJ, Sohn YH. The putamen to caudate nucleus ratio: A simple surrogate marker for dopaminergic volume in putamen. Movement Disorders. 2017;32(Supplement 2):1038-9.	4
193	Lee JM, Hong C, Ryu HS. A case of genetically confirmed chorea-acanthocytosis: Brain [18F]FDG-PET and [18F]FP-CIT-PET findings. Annals of Indian Academy of Neurology. 2020;23(3):369-71.	8
194	Lee JW, Hong JY, Oh JS, Lee I, Kim JS, Sohn YH, et al. Persistent drug-induced Parkinsonism with normal dopamine transporter imaging. Movement Disorders. 2016;31(Supplement 2):S293-S4.	4
195	Lee JY, Ju H, Im K, Ahn MY, Kwon KY. Relationship between striatal dopamine depletion and various nonmotor symptoms in non-demented patients with Parkinson's disease: A pilot study. Movement Disorder. 2019;34(Supplement 2):S802-S3.	4
196	Lee JY, Kim YK, Shin SA, Seo SH, Lee JS, Lee YS, et al. Alterations of cortical metabotropic glutamate receptor-mediated signaling in patients with Parkinson's disease. Movement Disorders. 2018;33(Supplement 2):S692.	4
197	Lee JY, Park SB, Lee M, Ju H, Im K, Kwon KY. Detailed visual assessment of striatal dopaminergic depletion in patients with idiopathic normal pressure hydrocephalus: Unremarkable or not? BMC Neurology. 2020;20(1) (no pagination)(277).	7
198	Lee JY, Seo S, Lee JS, Kim HJ, Kim YK, Jeon BS. Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology. 2015;85(10):853-60.	7
199	Lee JY, Seo SH, Kim HJ, Lee JS, Jeon B. Putaminal serotonergic fibers and levodopa-induced dyskinesias in Parkinson's disease patients. Movement Disorders. 2014;2):S87.	4
200	Lee JY, Seo SH, Kim YK, Lee JS, Jeon BS. Dopaminergic neural changes and impulse control related behavior disorder in Parkinson's disease. Movement Disorders. 2013;1):S132-S3.	4
201	Lee JY, Seo SH, Kim YK, Yoo HB, Kim YE, Song IC, et al. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2014;85(1):23-30.	7
202	Lee JY, Shin CM, Yun EJ, Kim YK, Jeon BS. Gastrointestinal symptom is a significant indicator of nigrostriatal dopaminergic degeneration in idiopathic rem sleep behavior disorder patients. Parkinsonism and Related Disorders. 2016;2):e117.	4
203	Lee JY, Yoon EJ, Kim YK, Shin CW, Nam H, Jeong JM, et al. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. Journal of Movement Disorders. 2019;12(2):103-12.	7
204	Lee KM, Kim HG, Kim EJ, Choi WS, Lee IY, Choi BS. Comparison with SWI and QSM techniques for evaluation of nigrosome-1 between normal and Parkinson disease subjects. International Journal of Computer Assisted Radiology and Surgery. 2017;12(1 Supplement 1):S205.	4

연번	서지정보	배제 사유
205	Lee KS, Kim JS, Lee JE. Contralateral Parkinson's disease in a patient with diabetic hemichorea. <i>Neurological Sciences</i> . 2018;39(9):1621-3.	2
206	Lee M, Ryu YH, Cho WG, Kang YW, Lee SJ, Jeon TJ, et al. Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. <i>Synapse</i> . 2015;69(9):453-60.	1
207	Lee MJ, Kim SL, Kim HI, Oh YJ, Lee SH, Kim HK, et al. [(18)F] FP-CIT PET study in parkinsonian patients with leukoaraiosis. <i>Parkinsonism & Related Disorders</i> . 2015;21(7):704-8.	7
208	Lee MJ, Kim SL, Lyoo CH, Rinne JO, Lee MS. Impact of regional striatal dopaminergic function on kinematic parameters of Parkinson's disease. <i>Journal of Neural Transmission</i> . 2015;122(5):669-77.	7
209	Lee MJ, Pak K. Genetic variations of SNCA and striatal dopaminergic dysfunction in patients with Parkinson's disease. <i>Movement Disorders</i> . 2018;33(Supplement 2):S627-S8.	4
210	Lee MJ, Pak K, Kim JH, Kim YJ, Yoon J, Lee J, et al. Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease. <i>Neurology</i> . 2019;93(7):e665-e74.	7
211	Lee R, Shin J, Choi H, Kim H. Variability of dopaminergic degeneration patterns in multiple system atrophy: Data-driven approaches of dopamine transporter PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2019;46(1 Supplement 1):S95.	4
212	Lee R, Shin JH, Choi H, Kim HJ, Cheon GJ, Jeon B. Variability of FP-CIT PET Patterns Associated With Clinical Features of Multiple System Atrophy. <i>Neurology</i> . 2021;96(12):e1663-e71.	7
213	Lee S, Cho E, Kim D, Kim J, Oh S. The most stable and fully automatic production of [18F]FP-CIT using All-in-One chemistry module. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S542-S3.	4
214	Lee SH, Kim HK, Lee YG, Lyoo CH, Ahn SJ, Lee MS. Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism. <i>Journal of Movement Disorders</i> . 2017;10(1):35-9.	7
215	Lee SH, Kim MS, Hwang YS, Jo SY, Jeon SR, Chung SJ. Association of presynaptic dopaminergic denervation with therapeutic effects of globus pallidus deep brain stimulation on freezing of gait in advanced Parkinson's disease. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S362.	4
216	Lee SH, Lee MJ, Lyoo CH, Cho H, Lee MS. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease. <i>Journal of Neural Transmission</i> . 2018;125(9):1333-9.	7
217	Lee SJ, Oh SJ, Chi DY, Kang SH, Kil HS, Kim JS, et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. <i>Nuclear Medicine and Biology</i> . 2007;34(4):345-51.	7
218	Lee SJ, Oh SJ, Moon WY, Choi MS, Kim JS, Chi DY, et al. New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: A 1.5-year production report. <i>Nuclear Medicine and Biology</i> . 2011;38(4):593-7.	7
219	Lee WW. The usefulness of a dual-phase 18-F-FP-CIT PET in a case of Alzheimer's disease with slow movement. <i>Movement Disorders</i> . 2020;35(SUPPL 1):S113-S4.	4
220	Leung K. (1R,2S,3S,5S)-Methyl-8-[[[(1S,2S)-2-(18F fluoromethyl) cyclopropyl]methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-2-carboxylate. National Center for Biotechnology Information. 2004.	7
221	Leung K. 2beta-Carbomethoxy-3beta-(4-chlorophenyl)-8-(2-[18F]fluoroethyl)nortropane. National Center for Biotechnology Information. 2004.	7
222	Leung K. 3-beta-(4-Iodophenyl)tropane-2-beta-carboxylic acid 2-[18F]fluoroethyl ester. National Center for Biotechnology Information. 2004.	7
223	Leung K. 8-((E)-4-Fluoro-but-2-enyl)-3beta-p-tolyl-8-aza-bicyclo[3.2.1]octane-2beta-carboxylic acid [11C]methyl ester. National Center for Biotechnology Information. 2004.	7
224	Leung K. N-4-[18F]Fluorobut-2-yn-1-yl-2beta-carbomethoxy-3beta-phenyltropane. National Center for Biotechnology Information. 2004.	7
225	Leung K. N-(3-[18F]Fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane. National Center for Biotechnology Information. 2004.	7
226	Leung K. N-(3-Fluoropropyl)-2beta-carbomethoxy-3beta-(4-[123I]iodophenyl)nortropane. National Center for Biotechnology Information. 2004.	7
227	Lim YM, Park HK, Kim JS, Lee CS, Chung SJ, Kim J, et al. Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome. <i>Neurological Sciences</i> . 2013;34(6):875-81.	7

연번	서지정보	배제 사유
228	Lokkegaard A, Werdelin LM, Regeur L, Karlsborg M, Jensen SR, Brødsgaard E, et al. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease. <i>European journal of nuclear medicine and molecular imaging</i> . 2007;34(4):508-16.	7
229	Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. <i>Journal of nuclear medicine</i> . 2004;45(10):1688-93.	6
230	Lyoo CH, Ryu YH, Lee MJ, Lee MS. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2012;126(5):344-9.	7
231	Ma H, Baik JS, Ahn HJ, Yoo WK, Kim YJ. Cognitive dysfunction in drug-induced Parkinsonism caused by prokinetics and antiemetics. <i>Journal of the Neurological Sciences</i> . 2015;1):e276.	4
232	Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. <i>Synapse</i> . 2002;45(2):125-33.	7
233	Maekawa T, Sato N, Ota M, Sugiyama A, Sone D, Enokizono M, et al. Correlations between dopamine transporter density measured by 123I-FP-CIT SPECT and regional gray matter volume in Parkinson's disease. <i>Japanese Journal of Radiology</i> . 2017;35(12):755-9.	7
234	Makinen E, Joutsa J, Vahlberg T, Kaasinen V. Survival in Parkinson's disease in relation to striatal dopamine transporter binding. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):593-4.	4
235	Marotta G, Cilia R, Belletti A, Siri C, Pezzoli G. Reversible dopamine transporter reduction in drug-induced Parkinsonism. <i>Clinical and Translational Imaging</i> . 2015;1):S89.	4
236	Masrori P, Van Weehaeghe D, Van Laere K, Van Damme P. Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging. <i>Journal of Nuclear Medicine</i> . 2021;62(9):1318-9.	8
237	Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naïve schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. <i>Psychopharmacology</i> . 2007;191(3):805-11.	6
238	Mattioli P, Pardini M, Fama F, Girtler N, Brugnolo A, Orso B, et al. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2021;48(9):2834-45.	6
239	McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. <i>Cochrane Database of Systematic Reviews</i> . 2015(1).	2
240	Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, et al. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. <i>Movement Disorders</i> . 2017;32(10):1482-6.	6
241	Meyer JH. Applying Neuroimaging Ligands to Study Major Depressive Disorder. <i>Seminars in Nuclear Medicine</i> . 2008;38(4):287-304.	2
242	Meyer PT, Amtage F, Hellwig S. [Differential diagnostics of Parkinson's disease with nuclear medicine procedures]. <i>Nervenarzt</i> . 2014;85(6):680-9.	3
243	Meyer PT, Hellwig S. Update on SPECT and PET in parkinsonism - part 1: imaging for differential diagnosis. <i>Current Opinion in Neurology</i> . 2014;27(4):390-7.	2
244	Min JH, Park DG, Yoon JH, An YS. Dual-Phase 18F-FP-CIT PET in Corticobasal Syndrome. <i>Clinical Nuclear Medicine</i> . 2019;44(1):e49-e50.	8
245	Miyagawa T, Przybelski SA, Maltais D, Min HK, Jordan L, Lesnick TG, et al. The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> . 2021;99:11-8.	6
246	Nct. Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease. https://clinicaltrials.gov/show/NCT04046276 . 2019.	4
247	Nct. [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor. https://clinicaltrials.gov/show/NCT04265209 . 2020.	4
248	Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, et al. N-substituted analogs of 2beta-carbomethoxy-3beta-(4'-iodophenyl)tropane (beta- CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. <i>Journal of Medicinal Chemistry</i> . 1996;39(2):543-8.	1

연번	서지정보	배제 사유
249	Nicastro N, Stripeikyte G, Assal F, Garibotto V, Blanke O. Premotor and fronto-striatal mechanisms associated with presence hallucinations in dementia with Lewy bodies. <i>NeuroImage Clinical</i> . 2021;32:102791.	7
250	Nikolaus S, Larisch R, Vosberg H, Beu M, Wirrwar A, Antke C, et al. Pharmacological challenge and synaptic response – Assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET). <i>Reviews in the Neurosciences</i> . 2011;22(6):625–45.	1
251	Nissen T, Malek N, Grosset KA, Newman EJ, Patterson J, Hadley D, et al. Baseline FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease. <i>Acta neurologica scandinavica</i> . 2014;129(3):204-8.	6
252	Noh Y, Sung YH, Lee J, Kim EY. Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality. <i>Ajnr: American Journal of Neuroradiology</i> . 2015;36(11):2010–6.	7
253	Oh E, Lim JG, Kim YS. The visible leg tremor at standing is always orthostatic tremor? <i>Movement Disorders</i> . 2016;31(Supplement 2):S323–S4.	4
254	Oh ES, Kim JM, Park SS, Kim YK, Kim SE, Oh SH, et al. Hemiparkinsonism-hemiatrophy syndrome: Neuroimaging and genetics. <i>Parkinsonism and Related Disorders</i> . 2012;2:S50–S1.	4
255	Oh J, Shen G, Nan G, Kim JM, Jung KY, Jeon B. Comorbid schizophrenia and Parkinson's disease: A case series and brief review. <i>Neurology Asia</i> . 2017;22(2):139–42.	2
256	Oh JK, Yoo ID, Seo YY, Chung YA, Yoo le R, Kim SH, et al. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. <i>Nuclear Medicine & Molecular Imaging</i> . 2011;45(4):255–60.	7
257	Oh JS, Lee I, Moon H, Oh M, Kim J. Striatum specific F-18 FP-CIT analysis in Parkinson disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S371–S2.	4
258	Oh M, Changhwan S, Seung Jun O, Sang Ju L, Jungsu SO, Sun Ju C, et al. Diagnostic performance of dual-phase F-18 FP-cit pet in the differential diagnosis of parkinsonism. <i>Neurodegenerative Diseases</i> . 2017;17(Supplement 1):1523.	4
259	Oh M, Oh SJ, Lee SJ, Oh JS, Roh JH, Chung SJ, et al. Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. <i>Clinical Nuclear Medicine</i> . 2020;45(11):841–7.	7
260	Oh SJ, Ahn H, Jung KH, Han SJ, Nam KR, Kang KJ, et al. Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model. <i>Molecular Imaging & Biology</i> . 2020;22(4):1031–42.	1
261	Oh YS, Kim JH, Yoo SW, Hwang EJ, Lyoo CH, Lee KS, et al. Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia. <i>Neurological Sciences</i> . 2021;42(2):711–8.	7
262	Oh YS, Kim JS, Hwang EJ, Lyoo CH. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease. <i>Parkinsonism & Related Disorders</i> . 2018;56:47–51.	7
263	Oh YS, Kim JS, Yoo SW, Hwang EJ, Lyoo CH, Lee KS. Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease. <i>Parkinsonism & Related Disorders</i> . 2019;63:156–61.	6
264	Oh YS, Kim JS, Yoo SW, Hwang EJ, Lyoo CH, Lee KS. Gender difference in the effect of uric acid on striatal dopamine in early Parkinson's disease. <i>European Journal of Neurology</i> . 2020;27(2):258–64.	7
265	Oh YS, Ryu DW, Kim JS, Lyoo CH. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease. <i>Movement Disorders</i> . 2018;33(Supplement 2):S675.	4
266	Oh YS, Yoo SW, Lyoo CH, Lee KS, Kim JS. The association of beta-amyloid with cognition and striatal dopamine in early, non-demented Parkinson's disease. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S369.	4
267	Orso B, Arnaldi D, Fama F, Girtler N, Brugnolo A, Doglione E, et al. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. <i>Cortex</i> . 2020;130:401–12.	6
268	Orso B, Arnaldi D, Girtler N, Brugnolo A, Doglione E, Mattioli P, et al. Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. <i>Movement Disorders</i> . 2021;36(10):2293–302.	7

연번	서지정보	배제 사유
269	Pagano G, Politis M. Molecular Imaging of the Serotonergic System in Parkinson's Disease. International Review of Neurobiology. 2018;141:173-210.	2
270	Pak K, Shin HK, Kim EJ, Lee JH, Lyoo CH, Son J, et al. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. Parkinsonism & Related Disorders. 2018;51:67-72.	6
271	Pak KJ, Lee MJ. Effect of polygenic load on striatal dopaminergic deterioration in Parkinson's disease. Movement Disorder. 2019;34(Supplement 2):S188-S9.	4
272	Pak KJ, Shin HK, Kim EJ, Lee JH, Lyoo CH, Son JS, et al. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. Movement Disorders. 2018;33(Supplement 2):S744-S5.	4
273	Park BN, Kim JH, Lee K, Park SH, An YS. Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT. European Radiology. 2014;11.	1
274	Park BN, Kim JH, Lee K, Park SH, An YS. Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT. European Radiology. 2015;25(5):1487-96.	1
275	Park C, Lee HJ, Kim JE, Lee DS, Kang KW. The study of reducing radiation exposure by developing 18F FP-CIT phantom. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2016;57(SUPPL. 2).	4
276	Park DG, An YS, Yoon JH. Serial 18F-FP-CIT and FDG PET in Fulminant Corticobasal Syndrome. Clinical Nuclear Medicine. 2021;46(9):754-5.	7
277	Park DG, Yoon JH, An YS. Normal presynaptic dopaminergic neurons in corticobasal syndrome with MAPT gene mutation. European Journal of Nuclear Medicine and Molecular Imaging. 2021;48(3):729-30.	7
278	Park HK, Kim JS, Im KC, Oh SJ, Kim MJ, Lee JH, et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses. Movement Disorders. 2009;24(2):237-45.	7
279	Park HK, Kim SM, Choi CG, Lee MC, Chung SJ. Effect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Movement Disorders. 2008;23(5):768-70.	7
280	Park HK, Lim YM, Kim JS, Lee MC, Kim SM, Kim BJ, et al. Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism. Journal of the Neurological Sciences. 2011;301(1-2):12-3.	8
281	Park I, Yoon W. Unilateral leg tremor on sitting crossed-legged position as the initial manifestation of Parkinson's disease. Movement Disorder. 2019;34(Supplement 2):S922.	4
282	Park JH, Park JY, Park SA, Lee TK, Sung KB. Effects of standard L-Dopa on saccadic eye movements in patients with mild-stage Parkinson's disease. Movement Disorders. 2011;26:S272-S3.	4
283	Park JS, Park D, Ko PW, Kang K, Lee HW. Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease. Neurological Sciences. 2017;38(10):1799-804.	7
284	Park KW, Ryu HS, Oh MY, Kim MJ, You S, Kim YJ, et al. Pre- and post-synaptic dopaminergic dysfunction and clinical features in multiple system atrophy. Journal of Parkinson's Disease. 2016;6(Supplement 1):160-1.	4
285	Park S, Choi JH, Yoon WT, Lee JY. Unilateral resting tremor in a thigh muscle in parkinson's disease. Tremor and Other Hyperkinetic Movements. 2020;10:1-3.	7
286	Park S, Lim JG, Chang HJ, Oh E. What Shall We Do for the Patients with Shaky Leg Syndrome? A Review of 23 Patients. Neurodegenerative Diseases. 2020;20(1):46-54.	2
287	Park SB, Kwon KY, Lee JY, Im K, Sunwoo JS, Lee KB, et al. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions. Neurological Sciences. 2019;40(2):311-7.	7
288	Park SD, Chi HM, Lee JH, Sung HJ, Lee BS, Chi DY. Selective preparation of azetidinium salt as [18F]FP-CIT precursor which provides high [18F]fluorination yield. Journal of Labelled Compounds and Radiopharmaceuticals. 2011;1(1):S509.	4
289	Park SH, Park HS, Kim BS, Lim SM, Yang S, Chang KT, et al. Quantitative PET analysis of subregional striatal dopaminergic neurodegeneration in the MPTP primate model of Parkinson's disease. Journal of Cerebral Blood Flow and Metabolism. 2017;37(1 Supplement 1):235-6.	4

연번	서지정보	배제 사유
290	Park SH, Park HS, Kim BS, Lim SM, Yang SJ, Chang KT, et al. Quantitative PET analysis of subregional striatal dopaminergic neurodegeneration in the MPTP primate model of Parkinson's disease. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2017;58(Supplement 1).	4
291	Park YS, Chung MY, Chang SK. Correlating parkinson's disease motor symptoms with 3-dimensional [18F]FP-CIT pet. Neuromodulation. 2013;16(5):e35.	4
292	Peng S, Doudet DJ, Dhawan V, Ma Y. Dopamine PET imaging and parkinson disease. PET Clinics. 2013;8(4):469-85.	2
2943	Pirker W. SPECT in the diagnosis of Parkin-sonism. [German]. Journal fur Neurologie, Neurochirurgie und Psychiatrie. 2015;16(2):60-71.	3
294	Polito C, Berti V, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiology of Aging. 2012;33(1):206.e29-39.	6
295	Puccini G, Frosini D, Guidoccio F, Manca G, Tardelli E, Ceravolo R, et al. FDG PET in the differential diagnosis of parkinsonisms: Utility of voxel-based analysis on individual basis. Clinical and Translational Imaging. 2017;5(Supplement 1):S26.	4
296	Reininger CB. The role of brain histopathology in neuro-pet and spect tracer development. Neuropathology. 2013;33(3):333.	4
297	Remy P. [Is functional imaging useful in the clinical evaluation of Parkinson's disease?]. Revue Neurologique. 2003;159(5 Pt 2):3S57-61.	2
298	Rissanen E, Kaasinen V, Sonninen P, Roytta M, Paivarinta M. Brain dopamine transporter binding and glucose metabolism in progressive supranuclear palsy-like creutzfeldt-jakob disease. Case Reports in Neurology. 2014;6(1):28-33.	6
299	Ryu HS, Hong CM. Brain F-18 FDG and F-18 FP-CIT PET/CT Findings of c.856_860delCTCTA Mutation McLeod Syndrome. Cognitive and Behavioral Neurology. 2021;34(3):207-11.	8
300	Ryu HS, Oh M, Kim MJ, You S, Kim YJ, Kim J, et al. Association between clinical features and pre-and post-synaptic dopaminergic dysfunction in multiple system atrophy: [18F]-FP-CIT PET and [18F]-FDG PET analyses. Movement Disorders. 2016;31(Supplement 2):S66.	4
301	Ryu HS, Oh M, Oh JS, Moon H, Park KW, Lee C, et al. Distinct clinical features of predominant pre-synaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy. Journal of the Neurological Sciences. 2019;402:100-6.	7
302	Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. The lancet Neurology. 2013;12(8):747-55.	6
303	Schmitz-Steinkruger H, Lange C, Apostolova I, Amthauer H, Lehnert W, Klutmann S, et al. Impact of the size of the normal database on the performance of the specific binding ratio in dopamine transporter SPECT. EJNMMI physics. 2020;7(1).	4
304	Schmitz-Steinkruger H, Lange C, Apostolova I, Amthauer H, Lehnert W, Klutmann S, et al. Impact of the size of the normal database on the performance of semi-quantitative analysis in dopamine transporter SPECT. Nuklearmedizin [Nuclear medicine]. 2020;59(2):182-.	6
305	Seibyl JP. Single-Photon Emission Computed Tomography and Positron Emission Tomography Evaluations of Patients With Central Motor Disorders. Seminars in Nuclear Medicine. 2008;38(4):274-86.	2
306	Seo J, Won J, Kim K, Park J, Yeo HG, Kim YG, et al. Impaired hand dexterity function in a non-human primate model with chronic Parkinson's disease. Experimental Neurobiology. 2020;29(5):376-88.	6
307	Seo M, Oh M, Cho M, Chung SJ, Lee CS, Kim JS. The Effect of SSRIs on the Binding of (18)F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nuclear Medicine & Molecular Imaging. 2014;48(4):287-94.	7
308	Seo S, Kim S, Kim Y, Jeon BS, Lee D, Lee J. Assessment of compatibility between early-frame image and R1 map in [18f]FP-CIT pet study. Molecular Imaging and Biology Conference. 2014;17(1 SUPPL. 1).	4
309	Seo S, Kim SJ, Yoo HB, Lee JY, Kim YK, Lee DS, et al. Noninvasive bi-graphical analysis for the quantification of slowly reversible radioligand binding. Physics in Medicine & Biology. 2016;61(18):6770-90.	7

연번	서지정보	배제 사유
310	Seo S, Lee JS, Yoo HB, Lee JY, Kim YK, Jeon BS, et al. Parametric mapping of [18F]FP-CIT dynamic PET based on graphical analysis for the assessment of abnormal dopamine transporter binding in Parkinson's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> . 2012;1):S144-S5.	4
311	Setani K, Habermeyer B, Reinartz P, Kosinski C. Suspected dementia of the Lewy body type: Diagnosis with 18F-FDG PET, 123I-IBZM and 123I-FP-CIT. [German]. <i>NuklearMedizin</i> . 2003;42(5):N56-N9.	3
312	Shih MC, Hoexter MQ, de Andrade LAF, Bressan RA. Parkinson's disease and dopamine transporter neuroimaging - A critical review. <i>Sao Paulo Medical Journal</i> . 2006;124(3):168-75.	2
313	Shin ES, Hwang O, Hwang YS, Suh JK, Chun YI, Jeon SR. Enhanced efficacy of human brain-derived neural stem cells by transplantation of cell aggregates in a rat model of Parkinson's disease. <i>Journal of Korean Neurosurgical Society</i> . 2014;56(5):383-9.	1
314	Shin HW, Chung SJ, Lee S, Cha J, Sohn YH, Yun M, et al. Dysautonomia Is Linked to Striatal Dopamine Deficits and Regional Cerebral Perfusion in Early Parkinson Disease. <i>Clinical Nuclear Medicine</i> . 2020;45(8):e342-e8.	7
315	Shin HW, Kim JS, Oh M, You S, Kim YJ, Kim J, et al. Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. <i>Neurological Sciences</i> . 2015;36(2):269-74.	7
316	Shin JH, Lee JY, Kim YK, Nam HW, Shin SA, Kim HJ, et al. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> . 2020;35(SUPPL 1):S586-S8.	4
317	Shin JH, Lee JY, Kim YK, Shin SA, Kim H, Nam H, et al. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. <i>Neurology</i> . 2020;95(23):e3081-e92.	7
318	Shin JH, Lee WW, Lee JY, Kim HJ, Jeon B. GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology. <i>Journal of Neurology</i> . 2020;267(7):1952-9.	7
319	Sinha N, Firbank M, O'Brien JT. Biomarkers in dementia with Lewy bodies: a review. <i>International Journal of Geriatric Psychiatry</i> . 2012;27(5):443-53.	2
320	Smilowska K, Burzynska-Makuch M, Brockhuis B, Piekarski R, Friedman A, Popek A, et al. Neuroimaging in Parkinson's Disease: necessity or exaggeration? <i>Neurologia i Neurochirurgia Polska</i> . 2021;19:19.	2
321	Sohara K, Sekine T, Tateno A, Mizumura S, Suda M, Sakayori T, et al. Multi-Atlas MRI-Based Striatum Segmentation for 123I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome. <i>Frontiers in Medicine</i> . 2021;8:662233.	6
322	Son HJ, Jeong YJ, Yoon HJ, Kang DY. The Parkinson disease related cortical and striatal cognitive pattern in early and delayed F-18 FP-CIT image: Evidence for neural correlates between caudate and frontal lobe. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	4
323	Son HJ, Jeong YJ, Yoon HJ, Kim JW, Choi G, Park JH, et al. Parkinson disease-related cortical and striatal cognitive patterns in dual time F-18 FP CIT: Evidence for neural correlates between the caudate and the frontal lobe. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2019;63(4):379-86.	7
324	Son HJ, Oh JS, Oh M, Lee SJ, Oh SJ, Chung SJ, et al. Test-retest reproducibility of dopamine transporter density measured with [18F]FP-CIT PET in patients with essential tremor and Parkinson's disease. <i>Annals of Nuclear Medicine</i> . 2021;35(3):299-306.	7
325	Song IU, Lee SH, Chung YA. The incidental suggestive meningioma presenting as high 18F FP-CIT uptake on PET/CT study. <i>Clinical Nuclear Medicine</i> . 2013;19.	8
326	Song IU, Lee SH, Chung YA. The incidental suggestive meningioma presenting as high 18F FP-CIT uptake on PET/CT study. <i>Clinical Nuclear Medicine</i> . 2014;39(1):e97-8.	8
327	Suh M, Im JH, Choi H, Kim HJ, Cheon GJ, Jeon B. Unsupervised clustering of dopamine transporter PET imaging discovers heterogeneity of parkinsonism. <i>Human Brain Mapping</i> . 2020;41(16):4744-52.	7
328	Sung C, Kim JS, Oh M, Oh SJ, Lee SJ, Oh J. Longitudinal decline of striatal subregional F-18 FP-CIT uptake in parkinson's disease. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	4

연번	서지정보	배제 사유
329	Sung C, Lee JH, Oh JS, Oh M, Lee SJ, Oh SJ, et al. Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. Nuclear Medicine & Molecular Imaging. 2017;51(4):304-13.	7
330	Sung YH, Lee J, Nam Y, Shin HG, Noh Y, Hwang KH, et al. Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T. Parkinsonism & Related Disorders. 2019;62:171-8.	7
331	Sung YH, Noh Y, Kim EY. Early-stage Parkinson's disease: Abnormal nigrosome 1 and 2 revealed by a voxelwise analysis of neuromelanin-sensitive MRI. Human Brain Mapping. 2021;42(9):2823-32.	6
332	Sung YH, Noh Y, Lee J, Kim EY. Drug-induced Parkinsonism versus Idiopathic Parkinson Disease: Utility of Nigrosome 1 with 3-T Imaging. Radiology. 2016;279(3):849-58.	7
333	Teune LK, Leenders KL. Molecular imaging in Parkinson's disease. Molecular Imaging in the Clinical Neurosciences. 2012;Neuroinformatics. 71:359-75.	2
334	Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calzagni ML, et al. 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and 123I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: a comparative study. Annals of neurology. 2016;80(3):368-78.	6
335	Van Der Gucht A, Cleret de Langavant L, Belissant O, Rabu C, Cottreau AS, Evangelista E, et al. Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Nuclear Medicine & Molecular Imaging. 2016;50(3):258-60.	8
336	Van Laere K, Everaert L, Annemans L, Gonce M, Vandenberghe W, Vander Borgh T. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. European Journal of Nuclear Medicine & Molecular Imaging. 2008;35(7):1367-76.	6
337	Verger A, Horowitz T, Chawki MB, Eusebio A, Bordonne M, Azulay JP, et al. From metabolic connectivity to molecular connectivity: application to dopaminergic pathways. European Journal of Nuclear Medicine & Molecular Imaging. 2020;47(2):413-24.	6
338	Villafane G, Thiriez C, Kerschen P, Itti E, Fenelon G, Cesaro P, et al. Efficacy of transdermal nicotine in advanced Parkinson's disease. A controlled open-label study in 40 patients randomised in two parallel groups. Movement disorders. 2014;29:S272-S3.	4
339	Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. British journal of psychiatry. 2015;206(2):145-52.	6
340	Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. Neurology. 2016;87(10):1045-51.	6
341	Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. Journal of Neurology. 2007;254(2):185-90.	7
342	Victor L, Victorin K, Widner H, Puschmann A. Wilson disease: Acute dystonia during treatment with SSRI or SNRI. Parkinsonism and Related Disorders. 2016;2:e140-e1.	4
343	Woo NE, Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH. Heterogeneous patterns of striatal dopamine loss in patients with young-versus old-onset Parkinson's disease. Movement Disorder. 2019;34(Supplement 2):S466.	4
344	Yang HJ, Park SH, Kim Y. 18F-labeled FP-CIT PET Findings in a series of cirrhotic patients with parkinsonism. Movement Disorders. 2017;32(Supplement 2):1075-6.	4
345	Yang HJ, Park SH, Seo M, Weon YC, Kim Y. 18F-FP-CIT dopamine transporter PET findings in cirrhotic patients with parkinsonism. Neurotoxicology. 2018;64:78-84.	7
346	Yang J, Sung YH, Park HM, Kim EY. Evaluation of the usefulness of SMw1 nigrosome 1 MRI for differentiating subclinical Parkinson's disease in idiopathic REM sleep behavior disorder. European Journal of Neurology. 2020;27(Supplement 1):379.	4
347	Yang Y. Clinical and FP-cit pet differences between parkinsons disease with and without agent orange exposure. Neurodegenerative Diseases. 2017;17(Supplement 1):1528.	4
348	Yang Y. Is Parkinson's disease with history of agent orange exposure different from idiopathic Parkinson's disease? Journal of the Neurological Sciences. 2017;381(Supplement 1):1050-1.	4

연번	서지정보	배제 사유
349	Yang Y, Cheon M, Kwak YT. Is Parkinson's Disease with History of Agent Orange Exposure Different from Idiopathic Parkinson's Disease? <i>Dementia and Neurocognitive Disorders</i> . 2016;15(3):75-81.	7
350	Yang Y, Cheon M, Kwak YT. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease. <i>Dementia and Neurocognitive Disorders</i> . 2017;16(3):57-63.	7
351	Yeop Kim E, Noh Y, Sung YH, Lee J, Seo S. In vivo nigrosome 1 and 4 imaging at 3T and Its Correlation with Dopamine Transporter imaging in Idiopathic Parkinson's Disease. <i>Neuroradiology</i> . 2018;60(1 Supplement 1):108-9.	4
352	Yoo D. Comorbid Moyamoya disease and Parkinson's disease: A case series. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S391.	4
353	Yoo D, Kim HG, Bang JI, Lee KM, Ahn TB. In vivo demonstration of selective vulnerability of dopamine neurons. <i>Journal of the Neurological Sciences</i> . 2020;415 (no pagination)(116946).	2
354	Yoo HS, Chung SJ, Kim SJ, Oh JS, Kim JS, Ye BS, et al. The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2018;45(9):1585-95.	7
355	Yoo HS, Chung SJ, Moon H, Oh JS, Kim JS, Hong JY, et al. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(3):423-31.	7
356	Yoo HS, Lee EC, Chung SJ, Lee YH, Lee SG, Yun M, et al. Effects of Alzheimer's disease and Lewy body disease on subcortical atrophy. <i>European Journal of Neurology</i> . 2020;27(2):318-26.	7
357	Yoo HS, Lee S, Chung SJ, Lee YH, Lee PH, Sohn YH, et al. Dopaminergic Depletion, beta-Amyloid Burden, and Cognition in Lewy Body Disease. <i>Annals of Neurology</i> . 2020;87(5):739-50.	7
358	Yoo HS, Lee S, Chung SJ, Ye BS, Sohn YH, Yun M, et al. Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. <i>Clinical Nuclear Medicine</i> . 2020;45(11):e463-e8.	7
359	Yoo SW, Kim JS. Contralateral levodopa-induced hemichorea in a patient with severe asymmetric Parkinson's disease. <i>Acta Neurologica Belgica</i> . 2020;120(3):691-3.	2
360	Yoo SW, Oh YS, Hwang EJ, Ryu DW, Lee KS, Lyoo CH, et al. "Depressed" caudate and ventral striatum dopamine transporter availability in de novo Depressed Parkinson's disease. <i>Neurobiology of Disease</i> . 2019;132:104563.	7
361	Yoo SW, Oh YS, Ryu DW, Lee KS, Lyoo CH, Kim JS. Low thalamic monoamine transporter availability is related to excessive daytime sleepiness in early Parkinson's disease. <i>Neurological Sciences</i> . 2020;41(5):1081-7.	7
362	Yook C, Lee S, Kim J, Dolle F, Oh S. Simple and highly efficient production of LBT999 with protic solvent system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S428-S9.	4
363	Yook CM, Lee SJ, Kim JS, Dolle F, Oh SJ. Simple and highly efficient automatic synthesis of [18F]LBT-999 with protic solvent. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> . 2015;1):S361.	4
364	Yoon EJ, Lee JY, Nam H, Kim HJ, Jeon B, Jeong JM, et al. A New Metabolic Network Correlated with Olfactory and Executive Dysfunctions in Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Journal of Clinical Neurology</i> . 2019;15(2):175-83.	7
365	Yoon HH, Min J, Shin N, Kim YH, Kim JM, Hwang YS, et al. Are human dental papilla-derived stem cell and human brain-derived neural stem cell transplantations suitable for treatment of Parkinson's disease? <i>Neural Regeneration Research</i> . 2013;8(13):1190-200.	1
366	Yoon HJ, Cho K, Kim WG, Jeong YJ, Jeong JE, Kang DY. Heterogeneity by global and textural feature analysis in F-18 FP-CIT brain PET images for diagnosis of Parkinson's disease. <i>Medicine</i> . 2021;100(35):e26961.	7
367	Yoon HJ, Jeong YJ, Son HJ, Kang DY. Diagnosis of MSA-C, MSA-P, and IPD by heterogeneity of brain metabolism in [18F] FP-CIT images. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	4
368	Yoon W. Asymmetrical resting legs tremor induced by levosulpiride. <i>Movement Disorders</i> . 2020;35(SUPPL 1):S42.	4

연번	서지정보	배제 사유
369	You S, Kim HW. The relative preservation of the nigral dopaminergic neuroal loss of the patients with Parkinson's disease having dopamineunresponsive resting tremor. Movement Disorders. 2015;1):S28.	4
370	You S, Kim HW. The relative preservation of the dopaminergic neuroal loss of patients with Parkinson's disease having dopamine-unresponsive resting tremor. Movement Disorders. 2017;32(Supplement 2):1006-7.	4
371	You S, Kim JS, Lee CS. Striatal pattern of [18F]FP-CIT binding is similar between pure akinesia and progressive supranuclear palsy. Movement Disorders. 2011;2):S255.	4
372	You S, Kim MJ, Kim SR, Kim JS, Chung SJ. Combined postural and rest tremors: Clinical and functional imaging characteristics. Movement Disorders. 2011;2):S377.	4
373	You S, Kim MJ, Kim SR, Kim MJ, Oh M, Kim JS, et al. [18F] FP-CIT pet analysis in patients with combined postural and rest tremors: Clinical correlation study. Parkinsonism and Related Disorders. 2012;2):S95.	4
374	You S, Kim MJ, Kim SR, Kim MJ, Oh M, Kim JS, et al. Clinical features and nigrostriatal dysfunction in patients with combined postural and resting tremors. Parkinsonism & Related Disorders. 2013;19(12):1118-22.	7
375	You S, Kim SR, Kim MJ, Oh M, Kim JS, Chung SJ. Quantitative analysis of dopamine transporter imaging in patients with Parkinson's disease: Between freezers and nonfreezers. Movement Disorders. 2012;1):S263.	4
376	You S, Kim SR, Kwon IH, Kim SJ, Chung SJ, Kim JS, et al. Factors determining the magnitude of levodopa response in patients with Parkinson's disease. Parkinsonism and Related Disorders. 2012;2):S120-S1.	4
377	Youn J, Lee SB, Lee HS, Yang HO, Park J, Kim JS, et al. Cerebrospinal Fluid Levels of Autophagy-related Proteins Represent Potentially Novel Biomarkers of Early-Stage Parkinson's Disease. Scientific Reports. 2018;8(1):16866.	7
378	Yousaf T, Dervenoulas G, Valkimadi PE, Politis M. Neuroimaging in Lewy body dementia. Journal of Neurology. 2019;266(1):1-26.	2
379	Yousaf T, Pagano G, Niccolini F, Politis M. Predict cognitive decline with non-clinical markers in Parkinson's disease. Movement disorders. 2017;32:641.	4
380	Yu KJ, Lee BJ, Han J, Park D. Usefulness of F-18 FP-CIT PET to predict dopamine-responsive hand tremor in patients other than Parkinson's disease: Two case reports. Medicine. 2018;97(22):e10983.	8
381	Yun JW, Ahn JB, Kwon E, Ahn JH, Park HW, Heo H, et al. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. Tissue Engineering and Regenerative Medicine. 2016;13(1):100-9.	1
382	Zanca M. Dopamine transporter and D2 receptor agonists to estimate the functional dopaminergic neuron terminals: Quantification methods in tomoscintigraphy. [French]. Medecine Nucleaire. 2002;26(11):625-35.	3
383	Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, et al. 123I FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Movement Disorders. 2007;22(9):1278-85.	6